Literature DB >> 11368138

Screening with a uterine Doppler in low risk pregnant women followed by low dose aspirin in women with abnormal results: a multicenter randomised controlled trial.

F Goffinet1, D Aboulker, J Paris-Llado, M Bucourt, M Uzan, E Papiernik, G Bréart.   

Abstract

OBJECTIVES: To assess whether systematic screening with an uterine artery Doppler in low risk pregnant women followed by the prescription of low dose aspirin in cases with abnormal results reduced the incidence of intrauterine growth restriction and pre-eclampsia.
DESIGN: A multicentre randomised trial. POPULATION: 3,317 low risk pregnant women. In the Doppler group, the uterine artery Doppler was performed between 20 and 24 weeks. Women with abnormal results received 100 mg of aspirin daily until the 35th week. MAIN OUTCOME MEASURES: Intrauterine growth restriction was defined as birthweight below the tenth and the third centile according to gestational age. Pre-eclampsia was defined as hypertension associated with proteinuria > 0.5g/L.
RESULTS: Intrauterine growth restriction, whether defined by the third or tenth centile, did not differ significantly between the two groups (RR = 1.22 [0.73 - 2.04] and 1.18 [0.93 - 1.51] respectively). Screening with uterine artery Doppler did not affect birthweight or any of the criteria of perinatal morbidity. There was no effect on the incidence of pre-eclampsia (RR = 1.99 [0.97 - 4.09]) or hypertensive disorders. These results were the same for nulliparae and multiparae.
CONCLUSIONS: There is no justification for screening with uterine artery Doppler in a low risk population, even if abnormal results are followed by aspirin treatment and increased prenatal surveillance. Future studies must assess predictive tests that can be performed early in pregnancy and can identify populations at very high risk of pre-eclampsia and intrauterine growth restriction. Only when all of these conditions are fulfilled, aspirin or other treatments may prove its efficacy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11368138     DOI: 10.1111/j.1471-0528.2001.00116.x

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  8 in total

1.  Uterine artery Doppler flow studies in obstetric practice.

Authors:  Rosalba Giordano; Alessandra Cacciatore; Mattea Romano; Beatrice La Rosa; Ilenia Fonti; Roberto Vigna
Journal:  J Prenat Med       Date:  2010-10

Review 2.  Fetal and umbilical Doppler ultrasound in normal pregnancy.

Authors:  Zarko Alfirevic; Tamara Stampalija; Nancy Medley
Journal:  Cochrane Database Syst Rev       Date:  2015-04-15

Review 3.  Fetal and umbilical Doppler ultrasound in normal pregnancy.

Authors:  Zarko Alfirevic; Tamara Stampalija; Gillian Ml Gyte
Journal:  Cochrane Database Syst Rev       Date:  2010-08-04

Review 4.  Utero-placental Doppler ultrasound for improving pregnancy outcome.

Authors:  Tamara Stampalija; Gillian Ml Gyte; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2010-09-08

5.  Low-dose aspirin to prevent preeclampsia and growth restriction in nulliparous women identified by uterine artery Doppler as at high risk of preeclampsia: A double blinded randomized placebo-controlled trial.

Authors:  Caroline Diguisto; Amelie Le Gouge; Marie-Sara Marchand; Pascal Megier; Yves Ville; Georges Haddad; Norbert Winer; Chloé Arthuis; Muriel Doret; Veronique Houfflin Debarge; Anaig Flandrin; Hélène Laurichesse Delmas; Denis Gallot; Pierre Mares; Christophe Vayssiere; Loïc Sentilhes; Marie-Therese Cheve; Anne Paumier; Luc Durin; Bruno Schaub; Veronique Equy; Bruno Giraudeau; Franck Perrotin
Journal:  PLoS One       Date:  2022-10-19       Impact factor: 3.752

6.  Antiplatelet agents for preventing pre-eclampsia and its complications.

Authors:  Lelia Duley; Shireen Meher; Kylie E Hunter; Anna Lene Seidler; Lisa M Askie
Journal:  Cochrane Database Syst Rev       Date:  2019-10-30

7.  Validation and development of models using clinical, biochemical and ultrasound markers for predicting pre-eclampsia: an individual participant data meta-analysis.

Authors:  John Allotey; Kym Ie Snell; Melanie Smuk; Richard Hooper; Claire L Chan; Asif Ahmed; Lucy C Chappell; Peter von Dadelszen; Julie Dodds; Marcus Green; Louise Kenny; Asma Khalil; Khalid S Khan; Ben W Mol; Jenny Myers; Lucilla Poston; Basky Thilaganathan; Anne C Staff; Gordon Cs Smith; Wessel Ganzevoort; Hannele Laivuori; Anthony O Odibo; Javier A Ramírez; John Kingdom; George Daskalakis; Diane Farrar; Ahmet A Baschat; Paul T Seed; Federico Prefumo; Fabricio da Silva Costa; Henk Groen; Francois Audibert; Jacques Masse; Ragnhild B Skråstad; Kjell Å Salvesen; Camilla Haavaldsen; Chie Nagata; Alice R Rumbold; Seppo Heinonen; Lisa M Askie; Luc Jm Smits; Christina A Vinter; Per M Magnus; Kajantie Eero; Pia M Villa; Anne K Jenum; Louise B Andersen; Jane E Norman; Akihide Ohkuchi; Anne Eskild; Sohinee Bhattacharya; Fionnuala M McAuliffe; Alberto Galindo; Ignacio Herraiz; Lionel Carbillon; Kerstin Klipstein-Grobusch; SeonAe Yeo; Helena J Teede; Joyce L Browne; Karel Gm Moons; Richard D Riley; Shakila Thangaratinam
Journal:  Health Technol Assess       Date:  2020-12       Impact factor: 4.014

8.  Prevalence of hypertensive disorders during pregnancy in France (2010-2018): The Nationwide CONCEPTION Study.

Authors:  Valérie Olié; Elodie Moutengou; Clémence Grave; Catherine Deneux-Tharaux; Nolwenn Regnault; Sandrine Kretz; Amélie Gabet; Claire Mounier-Vehier; Vassilis Tsatsaris; Geneviève Plu-Bureau; Jacques Blacher
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-05-27       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.